Last reviewed · How we verify
NCT05319457
Testing Radon Com Methods: Clinical Trial Smartphone App vs Print Brochures
NA trial testing The radon app in Lung Cancer in 130 participants. Completed in 1 September 2022.
5 August 2022
Quick facts
| Lead sponsor | University of North Dakota |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | prevention |
| Enrollment | 130 |
| Start date | 5 May 2022 |
| Primary completion | 5 August 2022 |
| Estimated completion | 1 September 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- The radon app
- Print brochure
Conditions studied
- Lung Cancer — all drugs for Lung Cancer →
Sponsor
University of North Dakota
Who can join
18 and older, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this research study is to compare the effectiveness of radon information delivered via the radon app vs. a traditional approach (printed brochure). The prevalence of exceptionally high levels of residential radon in ND, coupled with public's poor understanding of this hazard, is a critical public health problem.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Comparing Communication Methods to Increase Radon Knowledge and Home Testing: A Randomized Controlled Trial in a High-Radon City.
Kim S, Scheffer-Wentz H, Klug MG, Schwartz GG. · · 2023 · cited 2× · PMID 37174154 · DOI 10.3390/ijerph20095634
Verify or expand the search:
- PubMed search for NCT05319457
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of The radon app
Trials testing the same drug.
- NCT04980521 — Promoting Radon Testing Via Smartphone App: A Clinical Trial in a High Radon State · NA · completed
Other recruiting trials for Lung Cancer
Currently open trials in the same condition.
- NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
- NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
- NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting
Other University of North Dakota trials
Trials by the same sponsor.
- NCT05410327 — Health Effects of Traditional Indigenous Chokeberry · NA · completed
- NCT04980521 — Promoting Radon Testing Via Smartphone App: A Clinical Trial in a High Radon State · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05319457 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of North Dakota
- Last refreshed: 2 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05319457.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing